<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00419952</url>
  </required_header>
  <id_info>
    <org_study_id>D5896C00022</org_study_id>
    <nct_id>NCT00419952</nct_id>
  </id_info>
  <brief_title>A Comparison of SYMBICORT® pMDI With Budesonide HFA pMDI in African American Subjects With Asthma.</brief_title>
  <official_title>A 52-week, Randomised, Double-blind, Parallel-group, Multi-centre, Phase IIIB Study Comparing the Long Term Safety of SYMBICORT® pMDI 160/4.5 mg x 2 Actuations Twice Daily to Budesonide HFA pMDI 160 mg x 2 Actuations Twice Daily in Adult/Adolescent (≥12 Years) African American Subjects With Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effectiveness and safety of SYMBICORT® pMDI (a
      medication approved by the Food and Drug Administration, FDA) in the African American
      population.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Number of Asthma Exacerbations</measure>
    <time_frame>52 Weeks</time_frame>
    <description>An exacerbation was defined as symptomatic worsening requiring oral/systemic glucocorticoid therapy and/or emergency room visit and/or urgent care center visit and/or hospitalization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Asthma Exacerbations</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Number of participants with at least 1 exacerbation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QT Interval Corrected Using the Fridericia Formula Measured Via Electrocardiogram (ECG)</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>QT interval corrected using the Fridericia formula [QTc (Frid)] - Change from baseline to end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Shift From Normal to High Rate of Total Ectopic Ventricular Beats as Measured by 24-hour Holter Monitor Assessment</measure>
    <time_frame>Baseline and 2 weeks (visit 4)</time_frame>
    <description>Total ectopic ventricular (VE) beats - number of participants with shift from normal (&lt;50) to high (≥50) from baseline to visit 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Shift From Normal to High Rate of Total Ectopic Supraventricular Beats as Measured by 24-hour Holter Monitor Assessment</measure>
    <time_frame>Baseline and 2 weeks (visit 4)</time_frame>
    <description>Total ectopic supraventricular (VE) beats - number of participants with shift normal (&lt;50) to high (≥50) from baseline to visit 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of Ventricular Runs as Measured by 24-hour Holter Monitor Assessment</measure>
    <time_frame>Baseline and 2 weeks (visit 4)</time_frame>
    <description>Total ventricular runs - number of participants with shift normal (&lt;1) to high (≥1) from baseline to week 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diary Assessments - Rescue-free Day</measure>
    <time_frame>baseline and 52 weeks</time_frame>
    <description>Calculated as the number of rescue-free days divided by the number of non missing days in the baseline period times 100%. The results are expressed as the change in % rescue-free days in the baseline period and the active treatment period. A rescue-free day was one in which the patient answered &quot;no&quot; to having used rescue medication that day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diary Assessments - Symptom-free Day</measure>
    <time_frame>baseline and 52 weeks</time_frame>
    <description>Calculated as the number of symptom-free days divided by the number of non missing days in the baseline period times 100%. The results are expressed as the change in % symptom-free days in the baseline period and the active treatment period. A symptom-free day was one in which the patient answered &quot;no&quot; to having symptoms that day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diary Assessments - Asthma-control Day</measure>
    <time_frame>baseline and 52 weeks</time_frame>
    <description>Calculated as the number of asthma control days divided by the number of non missing days in the baseline period times 100%. The results are expressed as the change in % asthma control days in the baseline period and the active treatment period. An asthma control day was one in which the patient answered &quot;no&quot; to having symptoms and &quot;0&quot; to the use of rescue medication that day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Onset of Effect Questionnaire (OEQ)</measure>
    <time_frame>1 week</time_frame>
    <description>Number of participants with positive response to Item 2 in questionnaire &quot;During the past week,you could feel your study medication begin to work right away. A positive response was defined as a response of &quot;strongly agree&quot; or &quot;somewhat agree&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Onset of Effect Questionnaire (OEQ)</measure>
    <time_frame>1 week</time_frame>
    <description>Number of participants with positive response to Item 5 in questionnaire &quot;During the past week, you were satisfied with how quickly you felt your study medication begin to work.&quot; The scale was scored on a 5-point Likert scale from strongly agree to strongly disagree. A positive response was defined as a response of &quot;strongly agree&quot; or &quot;somewhat agree&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Expiratory Flow (PEF) in Morning</measure>
    <time_frame>baseline and 52 weeks</time_frame>
    <description>Change in AM PEF from baseline (mean over the 2 weeks run-in) to the average of the randomized treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in One Second (FEV1)</measure>
    <time_frame>baseline and 52 weeks</time_frame>
    <description>Change in pre-dose FEV1 from baseline (end of run-in, visit 3) to the average of the randomized treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma Treatment Satisfaction Measure (ATSM)</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <description>Overall score - change from baseline to end of treatment. For 11 individual attributes, expectations were subtracted from the outcomes. This difference and the importance rating were combined in a weighted average which was then multiplied by the raw satisfaction measure. The final derived satisfaction measure was transformed to a 0 to 100 scale, with higher scores representing greater satisfaction.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">742</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Symbicort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Symbicort pMDI 160/4.5 ug x 2 actuations twice daily (BID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Budesonide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Budesonide HFA pMDI 160 ug x 2 actuations BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide/formoterol (SYMBICORT) pMDI</intervention_name>
    <description>Symbicort pMDI 160/4.5 ug x 2 actuations twice daily (BID)</description>
    <arm_group_label>Symbicort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide HFA pMDI</intervention_name>
    <description>Budesonide HFA pMDI 160 ug x 2 actuations BID</description>
    <arm_group_label>Budesonide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or Female, African American (self-reported), ≥12 years of age

          -  Moderate to severe asthma requiring treatment with an inhaled corticosteroid

          -  Diagnosis of asthma for at least 6 months

        Exclusion Criteria:

          -  Subjects requiring treatment with systemic corticosteroids (e.g., oral, parenteral,
             ocular)

          -  Any significant disease or disorder that may jeopardize a subject's safety
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christer Hultquist, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montgomery</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Muscle Shoals</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Buena Park</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Foothill Ranch</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rolling Hills Estates</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stockton</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winnetka</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Altamonte Springs</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Destin</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Opa Locka</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Albany</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stone Mountain</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>River Forest</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Merrillville</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Owensboro</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bogalusa</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marrero</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Monroe</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sunset</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mitchellville</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montgomery Village</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wheaton</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dartmouth</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bay City</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paw Paw</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saginaw</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Prentiss</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vicksburg</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Blackwood</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cherry Hill</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Verona</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Newburgh</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>North Syracuse</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tonawanda</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Highpoint</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mooresville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lyndhurst</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Parma</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beaver</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Collegeville</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Harrisburg</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Havertown</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Upland</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yardley</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gaffney</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Simpsonville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Union</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Killeen</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Missouri City</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sugarland</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hampton</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Springfield</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2007</study_first_submitted>
  <study_first_submitted_qc>January 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2007</study_first_posted>
  <results_first_submitted>November 30, 2010</results_first_submitted>
  <results_first_submitted_qc>September 28, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 30, 2012</results_first_posted>
  <last_update_submitted>September 28, 2012</last_update_submitted>
  <last_update_submitted_qc>September 28, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Moderate Asthma</keyword>
  <keyword>Severe Asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First patient enrolled on 8 February 2007, the last patient completed the study on 30 November 2009. The study randomized participants only in the United States.</recruitment_details>
      <pre_assignment_details>The study included a run-in period of 2 weeks when all patients were prescribed budesonide HFA pMDI 160 μg times 2 actuations BID at individual daily doses and rescue medication, as needed. To be randomized to treatment the patients needed to show pre-dose FEV1 of ≥50%. One patient in the budesonide group did not receive any dose.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Symbicort</title>
          <description>Symbicort pMDI 160/4.5 ug x 2 actuations (twice daily) BID</description>
        </group>
        <group group_id="P2">
          <title>Budesonide</title>
          <description>Budesonide HFA pMDI 160 ug x 2 actuations (twice daily) BID</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="377"/>
                <participants group_id="P2" count="365"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="228"/>
                <participants group_id="P2" count="240"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="149"/>
                <participants group_id="P2" count="125"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Incorrectly enrolled</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Intake of prohibited medication</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Occurence of 2 or more exacerbations</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Diary or medication non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal ECG</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Symbicort</title>
          <description>Symbicort pMDI 160/4.5 ug x 2 actuations (twice daily) BID</description>
        </group>
        <group group_id="B2">
          <title>Budesonide</title>
          <description>Budesonide HFA pMDI 160 ug x 2 actuations (twice daily) BID</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="377"/>
            <count group_id="B2" value="365"/>
            <count group_id="B3" value="742"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.19" spread="15.67"/>
                    <measurement group_id="B2" value="38.35" spread="15.22"/>
                    <measurement group_id="B3" value="37.27" spread="15.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="249"/>
                    <measurement group_id="B2" value="232"/>
                    <measurement group_id="B3" value="481"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="128"/>
                    <measurement group_id="B2" value="133"/>
                    <measurement group_id="B3" value="261"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Number of Asthma Exacerbations</title>
        <description>An exacerbation was defined as symptomatic worsening requiring oral/systemic glucocorticoid therapy and/or emergency room visit and/or urgent care center visit and/or hospitalization.</description>
        <time_frame>52 Weeks</time_frame>
        <population>The full analysis set, consisting of all randomized patients who received at least one dose of randomized study medication and for whom data were collected after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>Symbicort pMDI 160/4.5 ug x 2 actuations (twice daily) BID</description>
          </group>
          <group group_id="O2">
            <title>Budesonide</title>
            <description>Budesonide HFA pMDI 160 ug x 2 actuations (twice daily) BID</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Asthma Exacerbations</title>
          <description>An exacerbation was defined as symptomatic worsening requiring oral/systemic glucocorticoid therapy and/or emergency room visit and/or urgent care center visit and/or hospitalization.</description>
          <population>The full analysis set, consisting of all randomized patients who received at least one dose of randomized study medication and for whom data were collected after randomization.</population>
          <units>Exacerbations</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="377"/>
                <count group_id="O2" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Asthma Exacerbations</title>
        <description>Number of participants with at least 1 exacerbation</description>
        <time_frame>52 Weeks</time_frame>
        <population>The full analysis set, consisting of all randomized patients who received at least one dose of randomized study medication and for whom data were collected after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>Symbicort pMDI 160/4.5 ug x 2 actuations (twice daily) BID</description>
          </group>
          <group group_id="O2">
            <title>Budesonide</title>
            <description>Budesonide HFA pMDI 160 ug x 2 actuations (twice daily) BID</description>
          </group>
        </group_list>
        <measure>
          <title>Asthma Exacerbations</title>
          <description>Number of participants with at least 1 exacerbation</description>
          <population>The full analysis set, consisting of all randomized patients who received at least one dose of randomized study medication and for whom data were collected after randomization.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="377"/>
                <count group_id="O2" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29" lower_limit="-1.01" upper_limit="0.79"/>
                    <measurement group_id="O2" value="51" lower_limit="-1.23" upper_limit="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>QT Interval Corrected Using the Fridericia Formula Measured Via Electrocardiogram (ECG)</title>
        <description>QT interval corrected using the Fridericia formula [QTc (Frid)] – Change from baseline to end of treatment</description>
        <time_frame>Baseline and 52 weeks</time_frame>
        <population>The full analysis set, consisting of all randomized patients who received at least one dose of randomized study medication and for whom data were collected after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>Symbicort pMDI 160/4.5 ug x 2 actuations (twice daily) BID</description>
          </group>
          <group group_id="O2">
            <title>Budesonide</title>
            <description>Budesonide HFA pMDI 160 ug x 2 actuations (twice daily) BID</description>
          </group>
        </group_list>
        <measure>
          <title>QT Interval Corrected Using the Fridericia Formula Measured Via Electrocardiogram (ECG)</title>
          <description>QT interval corrected using the Fridericia formula [QTc (Frid)] – Change from baseline to end of treatment</description>
          <population>The full analysis set, consisting of all randomized patients who received at least one dose of randomized study medication and for whom data were collected after randomization.</population>
          <units>msec</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="377"/>
                <count group_id="O2" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.11" lower_limit="-1.01" upper_limit="0.79"/>
                    <measurement group_id="O2" value="-0.31" lower_limit="-1.23" upper_limit="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Shift From Normal to High Rate of Total Ectopic Ventricular Beats as Measured by 24-hour Holter Monitor Assessment</title>
        <description>Total ectopic ventricular (VE) beats – number of participants with shift from normal (&lt;50) to high (≥50) from baseline to visit 4.</description>
        <time_frame>Baseline and 2 weeks (visit 4)</time_frame>
        <population>Data were available for a subset of patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>Symbicort pMDI 160/4.5 ug x 2 actuations (twice daily) BID</description>
          </group>
          <group group_id="O2">
            <title>Budesonide</title>
            <description>Budesonide HFA pMDI 160 ug x 2 actuations (twice daily) BID</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Shift From Normal to High Rate of Total Ectopic Ventricular Beats as Measured by 24-hour Holter Monitor Assessment</title>
          <description>Total ectopic ventricular (VE) beats – number of participants with shift from normal (&lt;50) to high (≥50) from baseline to visit 4.</description>
          <population>Data were available for a subset of patients.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Shift From Normal to High Rate of Total Ectopic Supraventricular Beats as Measured by 24-hour Holter Monitor Assessment</title>
        <description>Total ectopic supraventricular (VE) beats – number of participants with shift normal (&lt;50) to high (≥50) from baseline to visit 4.</description>
        <time_frame>Baseline and 2 weeks (visit 4)</time_frame>
        <population>Data were available for a subset of patients</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>Symbicort pMDI 160/4.5 ug x 2 actuations (twice daily) BID</description>
          </group>
          <group group_id="O2">
            <title>Budesonide</title>
            <description>Budesonide HFA pMDI 160 ug x 2 actuations (twice daily) BID</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Shift From Normal to High Rate of Total Ectopic Supraventricular Beats as Measured by 24-hour Holter Monitor Assessment</title>
          <description>Total ectopic supraventricular (VE) beats – number of participants with shift normal (&lt;50) to high (≥50) from baseline to visit 4.</description>
          <population>Data were available for a subset of patients</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Number of Ventricular Runs as Measured by 24-hour Holter Monitor Assessment</title>
        <description>Total ventricular runs – number of participants with shift normal (&lt;1) to high (≥1) from baseline to week 2.</description>
        <time_frame>Baseline and 2 weeks (visit 4)</time_frame>
        <population>Data were available for a subset of patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>Symbicort pMDI 160/4.5 ug x 2 actuations (twice daily) BID</description>
          </group>
          <group group_id="O2">
            <title>Budesonide</title>
            <description>Budesonide HFA pMDI 160 ug x 2 actuations (twice daily) BID</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Ventricular Runs as Measured by 24-hour Holter Monitor Assessment</title>
          <description>Total ventricular runs – number of participants with shift normal (&lt;1) to high (≥1) from baseline to week 2.</description>
          <population>Data were available for a subset of patients.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="13.43" upper_limit="18.34"/>
                    <measurement group_id="O2" value="1" lower_limit="8.11" upper_limit="13.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diary Assessments - Rescue-free Day</title>
        <description>Calculated as the number of rescue-free days divided by the number of non missing days in the baseline period times 100%. The results are expressed as the change in % rescue-free days in the baseline period and the active treatment period. A rescue-free day was one in which the patient answered “no” to having used rescue medication that day</description>
        <time_frame>baseline and 52 weeks</time_frame>
        <population>The full analysis set, consisting of all randomized patients who received at least one dose of randomized study medication and for whom data were collected after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>Symbicort pMDI 160/4.5 ug x 2 actuations (twice daily) BID</description>
          </group>
          <group group_id="O2">
            <title>Budesonide</title>
            <description>Budesonide HFA pMDI 160 ug x 2 actuations (twice daily) BID</description>
          </group>
        </group_list>
        <measure>
          <title>Diary Assessments - Rescue-free Day</title>
          <description>Calculated as the number of rescue-free days divided by the number of non missing days in the baseline period times 100%. The results are expressed as the change in % rescue-free days in the baseline period and the active treatment period. A rescue-free day was one in which the patient answered “no” to having used rescue medication that day</description>
          <population>The full analysis set, consisting of all randomized patients who received at least one dose of randomized study medication and for whom data were collected after randomization.</population>
          <units>Percentage of Rescue Free Day</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="369"/>
                <count group_id="O2" value="353"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.88" lower_limit="13.43" upper_limit="18.34"/>
                    <measurement group_id="O2" value="10.62" lower_limit="8.11" upper_limit="13.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diary Assessments - Symptom-free Day</title>
        <description>Calculated as the number of symptom-free days divided by the number of non missing days in the baseline period times 100%. The results are expressed as the change in % symptom-free days in the baseline period and the active treatment period. A symptom-free day was one in which the patient answered “no” to having symptoms that day</description>
        <time_frame>baseline and 52 weeks</time_frame>
        <population>The full analysis set, consisting of all randomized patients who received at least one dose of randomized study medication and for whom data were collected after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>Symbicort pMDI 160/4.5 ug x 2 actuations (twice daily) BID</description>
          </group>
          <group group_id="O2">
            <title>Budesonide</title>
            <description>Budesonide HFA pMDI 160 ug x 2 actuations (twice daily) BID</description>
          </group>
        </group_list>
        <measure>
          <title>Diary Assessments - Symptom-free Day</title>
          <description>Calculated as the number of symptom-free days divided by the number of non missing days in the baseline period times 100%. The results are expressed as the change in % symptom-free days in the baseline period and the active treatment period. A symptom-free day was one in which the patient answered “no” to having symptoms that day</description>
          <population>The full analysis set, consisting of all randomized patients who received at least one dose of randomized study medication and for whom data were collected after randomization.</population>
          <units>percentage of Symptom-free day</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="369"/>
                <count group_id="O2" value="353"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.46" lower_limit="7.55" upper_limit="11.37"/>
                    <measurement group_id="O2" value="7.58" lower_limit="5.62" upper_limit="9.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diary Assessments - Asthma-control Day</title>
        <description>Calculated as the number of asthma control days divided by the number of non missing days in the baseline period times 100%. The results are expressed as the change in % asthma control days in the baseline period and the active treatment period. An asthma control day was one in which the patient answered “no” to having symptoms and “0” to the use of rescue medication that day</description>
        <time_frame>baseline and 52 weeks</time_frame>
        <population>The full analysis set, consisting of all randomized patients who received at least one dose of randomized study medication and for whom data were collected after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>Symbicort pMDI 160/4.5 ug x 2 actuations (twice daily) BID</description>
          </group>
          <group group_id="O2">
            <title>Budesonide</title>
            <description>Budesonide HFA pMDI 160 ug x 2 actuations (twice daily) BID</description>
          </group>
        </group_list>
        <measure>
          <title>Diary Assessments - Asthma-control Day</title>
          <description>Calculated as the number of asthma control days divided by the number of non missing days in the baseline period times 100%. The results are expressed as the change in % asthma control days in the baseline period and the active treatment period. An asthma control day was one in which the patient answered “no” to having symptoms and “0” to the use of rescue medication that day</description>
          <population>The full analysis set, consisting of all randomized patients who received at least one dose of randomized study medication and for whom data were collected after randomization.</population>
          <units>percentage of Asthma-control day</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="369"/>
                <count group_id="O2" value="353"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.68" lower_limit="14.16" upper_limit="19.21"/>
                    <measurement group_id="O2" value="11.62" lower_limit="9.04" upper_limit="14.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Onset of Effect Questionnaire (OEQ)</title>
        <description>Number of participants with positive response to Item 2 in questionnaire “During the past week,you could feel your study medication begin to work right away. A positive response was defined as a response of “strongly agree” or “somewhat agree”</description>
        <time_frame>1 week</time_frame>
        <population>The full analysis set, consisting of all randomized patients who received at least one dose of randomized study medication and for whom data were collected after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>Symbicort pMDI 160/4.5 ug x 2 actuations (twice daily) BID</description>
          </group>
          <group group_id="O2">
            <title>Budesonide</title>
            <description>Budesonide HFA pMDI 160 ug x 2 actuations (twice daily) BID</description>
          </group>
        </group_list>
        <measure>
          <title>Onset of Effect Questionnaire (OEQ)</title>
          <description>Number of participants with positive response to Item 2 in questionnaire “During the past week,you could feel your study medication begin to work right away. A positive response was defined as a response of “strongly agree” or “somewhat agree”</description>
          <population>The full analysis set, consisting of all randomized patients who received at least one dose of randomized study medication and for whom data were collected after randomization.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="377"/>
                <count group_id="O2" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="172"/>
                    <measurement group_id="O2" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Onset of Effect Questionnaire (OEQ)</title>
        <description>Number of participants with positive response to Item 5 in questionnaire “During the past week, you were satisfied with how quickly you felt your study medication begin to work.” The scale was scored on a 5-point Likert scale from strongly agree to strongly disagree. A positive response was defined as a response of “strongly agree” or “somewhat agree”</description>
        <time_frame>1 week</time_frame>
        <population>The full analysis set, consisting of all randomized patients who received at least one dose of randomized study medication and for whom data were collected after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>Symbicort pMDI 160/4.5 ug x 2 actuations (twice daily) BID</description>
          </group>
          <group group_id="O2">
            <title>Budesonide</title>
            <description>Budesonide HFA pMDI 160 ug x 2 actuations (twice daily) BID</description>
          </group>
        </group_list>
        <measure>
          <title>Onset of Effect Questionnaire (OEQ)</title>
          <description>Number of participants with positive response to Item 5 in questionnaire “During the past week, you were satisfied with how quickly you felt your study medication begin to work.” The scale was scored on a 5-point Likert scale from strongly agree to strongly disagree. A positive response was defined as a response of “strongly agree” or “somewhat agree”</description>
          <population>The full analysis set, consisting of all randomized patients who received at least one dose of randomized study medication and for whom data were collected after randomization.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="377"/>
                <count group_id="O2" value="364"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165" lower_limit="46.19" upper_limit="49.80"/>
                    <measurement group_id="O2" value="157" lower_limit="43.95" upper_limit="47.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Expiratory Flow (PEF) in Morning</title>
        <description>Change in AM PEF from baseline (mean over the 2 weeks run-in) to the average of the randomized treatment period.</description>
        <time_frame>baseline and 52 weeks</time_frame>
        <population>The full analysis set, consisting of all randomized patients who received at least one dose of randomized study medication and for whom data were collected after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>Symbicort pMDI 160/4.5 ug x 2 actuations (twice daily) BID</description>
          </group>
          <group group_id="O2">
            <title>Budesonide</title>
            <description>Budesonide HFA pMDI 160 ug x 2 actuations (twice daily) BID</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Expiratory Flow (PEF) in Morning</title>
          <description>Change in AM PEF from baseline (mean over the 2 weeks run-in) to the average of the randomized treatment period.</description>
          <population>The full analysis set, consisting of all randomized patients who received at least one dose of randomized study medication and for whom data were collected after randomization.</population>
          <units>Liters/minute</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="364"/>
                <count group_id="O2" value="349"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.13" lower_limit="24.38" upper_limit="35.87"/>
                    <measurement group_id="O2" value="19.73" lower_limit="13.86" upper_limit="25.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in One Second (FEV1)</title>
        <description>Change in pre-dose FEV1 from baseline (end of run-in, visit 3) to the average of the randomized treatment period</description>
        <time_frame>baseline and 52 weeks</time_frame>
        <population>The full analysis set, consisting of all randomized patients who received at least one dose of randomized study medication and for whom data were collected after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>Symbicort pMDI 160/4.5 ug x 2 actuations (twice daily) BID</description>
          </group>
          <group group_id="O2">
            <title>Budesonide</title>
            <description>Budesonide HFA pMDI 160 ug x 2 actuations (twice daily) BID</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in One Second (FEV1)</title>
          <description>Change in pre-dose FEV1 from baseline (end of run-in, visit 3) to the average of the randomized treatment period</description>
          <population>The full analysis set, consisting of all randomized patients who received at least one dose of randomized study medication and for whom data were collected after randomization.</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="359"/>
                <count group_id="O2" value="354"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" lower_limit="0.05" upper_limit="0.11"/>
                    <measurement group_id="O2" value="-0.01" lower_limit="-0.04" upper_limit="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Asthma Treatment Satisfaction Measure (ATSM)</title>
        <description>Overall score - change from baseline to end of treatment. For 11 individual attributes, expectations were subtracted from the outcomes. This difference and the importance rating were combined in a weighted average which was then multiplied by the raw satisfaction measure. The final derived satisfaction measure was transformed to a 0 to 100 scale, with higher scores representing greater satisfaction.</description>
        <time_frame>Baseline and 52 weeks</time_frame>
        <population>The full analysis set, consisting of all randomized patients who received at least one dose of randomized study medication and for whom data were collected after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort</title>
            <description>Symbicort pMDI 160/4.5 ug x 2 actuations (twice daily) BID</description>
          </group>
          <group group_id="O2">
            <title>Budesonide</title>
            <description>Budesonide HFA pMDI 160 ug x 2 actuations (twice daily) BID</description>
          </group>
        </group_list>
        <measure>
          <title>Asthma Treatment Satisfaction Measure (ATSM)</title>
          <description>Overall score - change from baseline to end of treatment. For 11 individual attributes, expectations were subtracted from the outcomes. This difference and the importance rating were combined in a weighted average which was then multiplied by the raw satisfaction measure. The final derived satisfaction measure was transformed to a 0 to 100 scale, with higher scores representing greater satisfaction.</description>
          <population>The full analysis set, consisting of all randomized patients who received at least one dose of randomized study medication and for whom data were collected after randomization.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="203"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.99" lower_limit="46.19" upper_limit="49.80"/>
                    <measurement group_id="O2" value="45.64" lower_limit="43.95" upper_limit="47.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Symbicort</title>
          <description>Symbicort pMDI 160/4.5 ug x 2 actuations (twice daily) BID</description>
        </group>
        <group group_id="E2">
          <title>Budesonide</title>
          <description>Budesonide HFA pMDI 160 ug x 2 actuations (twice daily) BID</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="365"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oesophageal Fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Small Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="365"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Pneumonia Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Subcutaneous Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="365"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Foreign Body Trauma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Gun Shot Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Hip Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="365"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="365"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Uterine Leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="365"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="365"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="365"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus Urinary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="365"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhagic Ovarian Cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Ovarian Mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="365"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="365"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="365"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="98" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="365"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="365"/>
              </event>
              <event>
                <sub_title>Viral Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="365"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="365"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="377"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="365"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PI may use the Multi-Center Study Results and the Site Data for the limited purpose of his or her own research and academic analysis until the earlier of the publication of the first Multi-Center Study at all participating sites</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gerard Lynch</name_or_title>
      <organization>AstraZeneca</organization>
      <email>aztrial_results_posting@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

